DRUG PROVOCATION TEST AS A DIAGNOSTIC APPROACH FOR HYPERSENSITIVITY REACTION TO ANTITUBERCULOSIS DRUGS: A REPORT OF TWO CASES

Authors

  • KETUT SURYANA Department of Internal Medicine, Merpati Clinic HIV, Allergy-Clinical Immunology Services Unit, Wangaya Hospital, Denpasar, Bali, Indonesia.

DOI:

https://doi.org/10.22159/ajpcr.2020.v13i5.37248

Keywords:

Antituberculosis drug, Drug hypersensitivity reaction, Drug provocation test, Rapid desensitization

Abstract

Pulmonary tuberculosis (PTB) continues to be a public health problem, especially in developing countries. The necessity use of multidrug regimens of antituberculosis drug (ATD) in PTB treatment has been associated with increased risk of drug hypersensitivity reactions (DHRs). DHR is a type of unpredictable reaction, refers to immunologically mediated hypersensitivity reactions. It is observed more frequently in the intensive phase of the PTB treatment with varying degrees of severity. DHR can lead to reduce the patient adherence, thereby leading to stoppage of the drugs by the patient. The definite diagnosis based on drug provocation test (DPT) that should be performed at a hospital. The recommended therapeutic approach is rapid desensitization by reintroducing drugs in safety and optimal under threshold dose until usual daily dose is reached. We present two cases of DHR to ATD, DPT as the diagnosis and rapid desensitization as the therapeutic approach.

Downloads

Download data is not yet available.

References

Fei CM, Zainal H, Ali IA. Evaluation of adverse reactions induced by anti-tuberculosis drugs in hopsital pulau Pinang. Malays J Med Sci 2018;25:103-14.

Venkateswarlu K, Tiwari K, Mamatha E, Vivek S, Shravan P. Study of adverse drug reactions in tuberculosis patients. J Pharma Res 2017;6:61-5.

Honnaddi UC, Honnaddi MU, Tharangini SR, Hossain T, Somani R. Adverse drug reactions to first line anti-tuebrculosis drugs-a pharmacovigilance study. Int J Pharmacol Res 2016;6:51-4.

Health Ministry Republic of Indonesia. Current Status of Integrated Community Based TB Service Delivery and the Global Fund Work Plan to Find Missing TB Cases. Indonesia: Indonesia National TB Program, Health Ministry Republic of Indonesia; 2017.

Johansson SG, Hourihane JO, Bousquet J, Koomen CB, Dreborg S, Haahtela T, et al. A revised nomenclature for allergy an EAACI position statement from the EAACI nomenclature task force. Allergy 2001;56:813-24.

Singh A, Sayedda K, Ahmed QS. Comparison of adverse drug reactions of antitubercular drugs in category 1 tuberculosis patients between daily and intermittent regimen and its impact on outcome. J Res Med Dent Sci 2017;5:6-12.

Gulbay BE, Gurkan OU, Yildiz OA, Onen ZP, Erkekol FO, Baccioglu A, et al. Side effects due to primary antituberculosis drugs during the initial phase of therapy in 1149 hospitalized patients for tuberculosis. Respir Med 2006;100:1834-42.

Behera C, Krishna K, Singh HR. Antitubercular drug-induced violent suicide of a hospitalized patient. BMJ Case Rep 2014;2014:1-3.

Alqahtani JM, Assad AM. Anti-Tuberculous drugs and susceptibility testing methods: Current knowledge and future challenges. J Mycobac Dis 2014;4:1-6.

Aberer W, Bircher A, Romano A, Blanca M, Campi P, Frenandez, et al. Drug provocation testing in the diagnosis of drug hypersensitivity reactions: General considerations. Allergy 2003;58:854-63.

Bianchi PG, Aun MV, Galvao VR, Castells M. Rapid desensitization in immediate hypersensitivity reaction to drugs. Curr Treat Options Allergy 2015;2:268-85.

Vaghela JH, Nimbark V, Barvaliya M, Mehta H, Chavada B. Antituberculosis drug-induced fixed druh eruption: A case report. Drug Saf Case Rep 2018;5:23.

Gholami K, Kamali E, Hajiabdolbaghi M, Shalviri G. Evaluation of anti-tuberculosis induced adverse reactions in hospitalized patients. Pharm Pract 2006;4:134-8.

Messaad D, Sahla H, Benahmed S, Godard P, Bousquet J, Demoly P. Drug provocation tests in patients with a history suggesting an immediate drug hypersensitivity reaction. Ann Intern Med 2004;140:1001-6.

Limsuwan T, Castells MC. Outcomes and safety of rapid desensitization for chemotherapy hypersensitivity. Expert Opin Drug Saf 2010;9:39-53.

Castelss M. Rapid desensitization for hypersensitivity reactions to medications. Immunol Allergy Clin N Am 2009;29:585-606.

Macy E, Romano A, Khan D. Practical Management of antibiotic hypersensitivity in 2017. J Allergy Clin Immunol Pract 2017;5:577-86.

Chiriac AM, Demoly P. Drug provocation tests: Up-date and novel approaches. Allergy Asthma Clin Immunol 2013;9:12

Solensky R. Desensitization with antibiotics. In: Pichler WJ, editor. Drug Hypersensitivity. Basel: Karger; 2007. p. 404-12.

Garvey LH, Ebo DG, Kroigaard M, Savic S, Clarke R, Cooke P, et al. The use of drug provocation testing in the investigation of suspected immediate perioperative allergic reactions: Current status. Br J Anaesth 2019;123:e126-34.

Farazi A, Sofian M, Jabbariasl M, Keshavarz S. Adverse reactions to antituberculosis drugs in Iranian tuberculosis patients. Tuberc Res Treat 2014;2014:1-6.

Hu X, Zhang M, Bai H, Wu L, Chen Y, Ding L, et al. Antituberculosis drug-induced adverse events in the liver, kidneys, and blood: Clinical profiles and pharmacogenetic predictors. Clin Pharmacol Ther 2018;104:326-34.

Amin S, Mishra V, Desai M, Solanki R. Pattern of adverse drug reactions and its potential impact on drug resistant tuberculosis patients at a tertiary care teaching hospital in Western India. Clin J Pharmacol Pharmacother 2018;1:15-20.

Cernadas JR, Brockow K, Romano A, Aberer W, Torres MJ, Bircher A, et al. General considerations on rapid desensitization for drug hypersensitivity-a consensus statement. Allergy 2010;65:1357-66.

Published

07-05-2020

How to Cite

SURYANA, K. “DRUG PROVOCATION TEST AS A DIAGNOSTIC APPROACH FOR HYPERSENSITIVITY REACTION TO ANTITUBERCULOSIS DRUGS: A REPORT OF TWO CASES”. Asian Journal of Pharmaceutical and Clinical Research, vol. 13, no. 5, May 2020, pp. 1-4, doi:10.22159/ajpcr.2020.v13i5.37248.

Issue

Section

Case Study(s)

Most read articles by the same author(s)